The highly immunogenic nature is a further characteristic of RCC,12 being the basis for already outdated therapeutic approaches with interleukin (IL)-2 and interferon-α (IFN-α) as well as the to date cutting-edge RCC treatment with immune checkpoint inhibitors (ICIs).10,13, , , , , , –20. The gene discussed is IL2; the disease is renal cell adenocarcinoma.